Specialties
Oncology Billing Services
In oncology, a single treatment day can carry more revenue than a month of office visits, and most of it is the drug. The claim depends on infusion start and stop times, the administration hierarchy, drug units calculated from the dose, any discarded amount, and an authorization that covers that drug for that cycle.
- Infusion times captured and coded through the administration hierarchy
- Drug units and discarded amounts reconciled to every vial opened
- Authorizations tracked by regimen, drug and treatment cycle
Infusion time, drug units and the administration hierarchy
Only one initial drug administration service is reported per encounter, with sequential and concurrent codes for the rest. On physician claims Medicare treats the initial service as the primary reason for the encounter, while facilities choose it by the hierarchy of chemotherapy, then therapeutic infusion, then hydration. Additional infusion hours are billed only when the infusion runs more than 30 minutes into the next hour. Without accurate start and stop times in the record, neither the hierarchy nor the hours can be supported.
The drug line is where most of the money is. Units are calculated from the dose given and the amount in the HCPCS descriptor, discarded drug from a single-dose vial is billed with its own modifier for Medicare, and the payment rate for most Part B drugs is based on average sales price, which CMS updates quarterly. We track the current payment limits rather than quoting them, and check every payment against them.
Authorization in oncology is rarely one-and-done. Payers often approve a specific regimen for a set number of cycles or a date range, and a change of drug, dose or biosimilar product can require a new approval. A frequent denial follows a product switch: the approval names one biosimilar or reference product and a different one is given, so we compare the product given with the approval on every treatment day.
Official source: CMS: Medicare Part B Drug Payment Limit Files (external site)
Oncology drug administration and treatment codes
Administration and treatment codes medical and radiation oncology practices bill most. Confirm with current CPT and payer policy.
| Codes or modifiers | Service | Billing notes |
|---|---|---|
| 96413, 96415, 96417 | Chemotherapy IV infusion: first hour, each additional hour, and each sequential new drug. | Additional hours require the infusion to run past the time threshold; times must be documented. |
| 96409, 96411 | Chemotherapy IV push, first drug and each additional drug. | A push is an infusion of 15 minutes or less, or one given by a clinician who stays with the patient. |
| 96365 to 96368, 96360, 96361 | Therapeutic infusions (initial, additional hour, sequential, concurrent) and hydration. | Ranked below chemotherapy in the hierarchy; hydration alongside chemotherapy has rules of its own. |
| J-codes, JW, JZ | The drug in HCPCS units, discarded drug, and no drug discarded. | Medicare expects JW for discarded amounts from single-dose containers and JZ when none was discarded. |
| TB | Modifier identifying drugs acquired through the 340B program. | Required from all 340B covered entities on separately payable Medicare Part B drug lines; the former JG modifier has been discontinued. |
| 77427 | Radiation treatment management, per five fractions. | The physician's weekly management of a course of radiation. |
| Q0, Q1, Z00.6 | Investigational item or service, routine clinical service in a trial, and the trial encounter diagnosis. | Used for Medicare-qualifying clinical trials along with the trial's NCT number. |
CPT is a registered trademark of the American Medical Association.
Official sources: CMS Claims Processing Manual, chapter 12 (drug administration) (external site), CMS Medicare Coverage Database: article A54635 (infusion and hydration) (external site), CMS: Revised 340B modifier guidance (external site), CMS Claims Processing Manual, chapter 17 (JW and JZ) (external site), CMS Medicare Coverage Database: NCD 310.1 (clinical trials) (external site), CMS Claims Processing Manual, chapter 32 (clinical trial claims) (external site), CMS Claims Processing Manual, chapter 13 (external site), CMS: relative value file (external site), CMS coverage database: article A53778 (external site), CMS coverage database: article A57554 (external site), CMS: average sales price (external site)
Medical oncology compared with radiation oncology
Groups that offer both need separate billing setups for each.
| Area | Medical oncology | Radiation oncology |
|---|---|---|
| Main revenue | Drugs and their administration. | Treatment planning, simulation and delivery, with weekly management. |
| Unit of billing | Per infusion and per drug unit. | Per fraction for delivery and per five fractions for management. |
| Technical and professional split | Mostly billed globally in the office. | Often split between a facility and the physician group. |
| Authorization | Per drug, regimen and cycle. | Per course of treatment and technique, such as IMRT. |
From authorization to infusion: how each treatment day is billed
Step 1: Authorize by regimen and cycle
Each regimen's drugs, doses and cycles are checked against the approval before the treatment date.
Step 2: Abstract the infusion record
Start and stop times, sequence and routes come from the infusion record to apply the hierarchy correctly.
Step 3: Reconcile every vial
Units given and discarded are matched to the vials opened, with JW or JZ on each single-dose drug line.
Step 4: Check payment against current limits
Drug payments are compared with the current quarter's payment limit or the contract rate.
Step 5: Route trial and pharmacy-supplied drugs
Trial patients and drugs supplied by a specialty pharmacy are flagged so only the right services are billed.
Clinical trials, 340B and specialty pharmacy drugs
In qualifying clinical trials Medicare covers the routine costs, but not the investigational item itself when the sponsor provides it, so trial claims need the modifiers, diagnosis and trial number that separate the two. Commercial plans have their own trial coverage rules, which we check before the patient enrolls.
Hospital-based and other 340B covered entities buy many drugs at a discount and must identify those drugs on Medicare claims. Independent practices buy and bill instead, carrying the drug cost until payment arrives. When a plan sends the drug through a specialty pharmacy, sometimes called white bagging, we flag the dose at intake so the claim carries only the services the practice provided and no drug line for a product it never bought.
Oncology denials worth preventing
Authorization does not cover this cycle
The approval expired, covered fewer cycles, or named a different drug, dose or biosimilar.
Units do not match the dose
Drug units calculated from the vial size instead of the dose given, or rounding the payer does not accept.
Missing JW or JZ
A single-dose drug line without the wastage modifier Medicare expects.
Administration hierarchy wrong
Two initial infusion codes in one encounter, or hydration billed as the initial service on a chemotherapy day.
Infusion hours without stop times
Additional hours billed without documented start and stop times.
Trial claims without trial identifiers
Routine trial costs billed without the NCT number, diagnosis or modifiers, or investigational items billed to the payer.
Frequently asked questions
How are additional infusion hours counted?
The first hour is the initial code, and each additional hour is billed only when the infusion continues more than 30 minutes into that hour, based on documented start and stop times.
What do JW and JZ mean on oncology claims?
JW reports drug discarded from a single-dose vial or package, and JZ confirms none was discarded. Medicare expects one of them on single-dose drug lines.
Does a new treatment cycle need a new authorization?
Often. Approvals usually cover a set number of cycles or a date range, and a change of drug, dose or product can require a new request even within a regimen.
How do we bill a patient enrolled in a clinical trial?
Routine costs are billed with the trial diagnosis, the NCT number and the routine-service modifier, while items the sponsor provides free are not billed to the payer. Commercial plans need a coverage check first.
Why do drug payment rates keep changing?
Medicare pays most Part B drugs based on average sales price, which CMS updates every quarter, and contracts often reference it. We track the current files and check each payment against them.
Official source: CMS: Medicare Part B Drug Payment Limit Files (external site)
Related services and specialties
Related services
Prior Authorization
Authorization requirements checked, requests submitted with clinical support, and approvals matched to claims before the service date.
Learn more about Prior AuthorizationMedical Coding
E/M, procedure and diagnosis coding from the documentation, with modifier, NCCI and MUE checks before claims go out.
Learn more about Medical Coding
Specialties
Radiology Billing
Global, professional and technical component billing, imaging authorizations through benefit managers, contrast coding and ordering-provider rules.
Learn more about Radiology BillingLaboratory Billing
Lab billing under the clinical lab fee schedule: CLIA matching, diagnosis linking to NCDs and LCDs, panels, molecular tests, toxicology and client billing.
Learn more about Laboratory Billing
Protect the revenue on every treatment day
A free audit reviews drug units and wastage, the administration hierarchy, and authorization denials across your oncology claims.